PPD, Inc. announced it has launched an online portal linking clinical trial participants with biopharmaceutical companies, physicians, and healthcare resources to enhance patient connectivity and improve retention in clinical trials.
PPD PatientView is a secure online technology empowering clinical trial participants to view, share, and electronically archive medical information related to their illness, enabling them to play a more active role in managing their health and actively engaging them throughout the duration of a clinical trial.
"Regulatory agencies are requiring longer, more complex clinical studies, increasing the likelihood of patients leaving a clinical study before it's completed," said Mike Wilkinson, executive vice president and chief information officer for PPD. "The loss of patients during a trial can lead to increased costs and delay the trial's completion. PPD PatientView empowers patients by enabling better communication with the study team, better connectivity with study activities and better access to information about their individual disease."
PPD PatientView is customizable, allows patients online access to valuable health information, and is a convenient way to stay in continual contact with the trial registry and monitoring program. The portal leverages Microsoft HealthVault, a personal health application platform that lets consumers gather, store and share health information online.
PPD PatientView is a part of PPD® Adaptive Solutions, the suite of integrated technology solutions that PPD deploys to meet each client's needs in advancing their research initiatives. PPD and Microsoft have announced plans to jointly implement a technology solution to improve efficiency in managing U.S. Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) programs. PPD also was recognized on the 2010 InformationWeek 500, a list of the nation's most innovative users of business technology.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.